Captor Therapeutics Spolka Akcyjna (CTX.WA)
PLN 35.4
(5.36%)
PLN 35.4
(5.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -64.76 Million PLN | -162.23% |
| 2022 | -28.22 Million PLN | -14.76% |
| 2021 | -24.41 Million PLN | -335.46% |
| 2020 | -5.61 Million PLN | -66.73% |
| 2019 | -3.41 Million PLN | -117.71% |
| 2018 | -1.57 Million PLN | -436.91% |
| 2017 | 466 Thousand PLN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.26 Million PLN | 19.86% |
| 2024 Q2 | -9.4 Million PLN | -3.66% |
| 2023 Q4 | -15.5 Million PLN | -6.95% |
| 2023 Q1 | -12.55 Million PLN | -160.66% |
| 2023 Q3 | -14.49 Million PLN | 47.29% |
| 2023 FY | - PLN | -162.23% |
| 2023 Q2 | -27.49 Million PLN | -119.08% |
| 2022 Q2 | -7.87 Million PLN | 12.11% |
| 2022 FY | - PLN | -14.76% |
| 2022 Q4 | -4.81 Million PLN | 29.61% |
| 2022 Q3 | -6.84 Million PLN | 13.09% |
| 2022 Q1 | -8.95 Million PLN | 0.63% |
| 2021 Q2 | -4.34 Million PLN | -27.47% |
| 2021 Q4 | -9.01 Million PLN | -11.84% |
| 2021 Q3 | -8.05 Million PLN | -85.52% |
| 2021 FY | - PLN | -335.46% |
| 2021 Q1 | -3.4 Million PLN | -1076.22% |
| 2020 FY | - PLN | -66.73% |
| 2020 Q3 | -4.4 Million PLN | 0.0% |
| 2020 Q4 | 349 Thousand PLN | 107.93% |
| 2019 FY | - PLN | -117.71% |
| 2018 FY | - PLN | -436.91% |
| 2017 FY | - PLN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioceltix S.A. | -13.22 Million PLN | -389.732% |
| BIOTON S.A. | 43.89 Million PLN | 247.536% |
| Mabion S.A. | 58.31 Million PLN | 211.063% |
| Molecure S.A. | -25.5 Million PLN | -153.919% |
| NanoGroup S.A. | -7.87 Million PLN | -722.895% |
| Pharmena S.A. | 33.78 Million PLN | 291.723% |
| Poltreg S.A. | -11.65 Million PLN | -455.485% |
| Pure Biologics Spólka Akcyjna | -26.07 Million PLN | -148.357% |
| Ryvu Therapeutics S.A. | -81.04 Million PLN | 20.088% |
| Synthaverse S.A. | 15.34 Million PLN | 522.025% |
| Urteste S.A. | -5.73 Million PLN | -1030.065% |